Health Evaluation in African Americans Using RAS Therapy

• Status: Recruiting
• Trial end date: 2022-02-28
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if Telmisartan, an FDA approved blood pressure medication, may also have beneficial effects on Alzheimer's disease prevention in African Americans, who are at high risk for Alzheimer's disease.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Emory University
• Treatments: Telmisartan

Criteria

Inclusion Criteria:

1. Treated hypertension (systolic blood pressure ≥ 110 mmHg systolic and ≤ 170 mmHg

2. Parent or biological family member with Alzheimer's disease

3. African American

Exclusion Criteria:

1. Mean resting blood pressure ≥110 and ≤ 170 mmHg systolic

2. Currently in another investigational drug study

3. Current use of renin-angiotensin acting medication

4. Potassium >5.5 meq/dl at baseline

5. Creatinine >1.99 mg/dl at baseline

6. History of stroke

7. Dementia

8. Baseline Montreal Cognitive Assessment score <27

9. Contraindication for lumbar puncture or magnetic resonance imaging

10. Heart failure

11. Diabetes Types I and II

12. Pregnant or nursing women